At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 12 target
Drug / intervention
Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Early Exploratory Clinical Trial of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma.
In Brief
A Phase 1 clinical trial evaluating Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Targeting 12 participants across 1 site.
Detailed Summary
A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsGracell Biopharmaceuticals, Inc.
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartNov 2023
First PostedApr 2024
Primary CompletionNov 2025
TodayJul 2026
First PostedApr 8, 2024
Enrollment StartNov 17, 2023
Primary CompletionNov 16, 2025
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.2 years ago
Interventions
Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injectiondrug
single-/multiple-dose infusion